Morphotek Announces Appointments to Scientific Advisory Board

Morphotek Inc. announced today the following appointments to its Scientific Advisory Board. Appointed to the Board were Dr. Matthias Wabl, Professor of Microbiology and Immunology at the University of California, San Francisco, and Dr. Wafik El-Deiry, Associate Professor of Medicine and practicing oncologist at the University of Pennsylvania School of Medicine and Howard Hughes Investigator.

"We are delighted to have these top-tiered researchers with expertise in immunology, antibody maturation and molecular oncology providing us with advice to strengthen Morphotek's growing platform technology and business focus in the area of antibody therapeutics and clinical oncology," commented Nicholas C. Nicolaides, Ph.D., President and Chief Executive Officer.

Dr. Wabl is a professor of Microbiology and Immunology at the University of California, San Francisco. He is an expert in the area of antibody maturation and somatic cell hypermutation. His pioneering work has led to fundamental understanding of molecular mechanisms involved in antibody gene recombination and hypermutation to yield high-affinity antibodies to target antigens.

Dr. El-Deiry is an Associate Professor of Medicine and practicing oncologist at the University of Pennsylvania School of Medicine, Member of the Penn Comprehensive Cancer Center and a Howard Hughes Investigator. He is an expert in the area of molecular oncology and cell cycle regulation. His research has led to a number of cutting-edge discoveries on the genetic basis of cancer and mechanisms of deregulated cell growth of cancer cells. He is a practicing oncologist and brings relevant clinical experience for administration of approved and experimental cancer therapies.

Morphotek (www.morphotek.com) is a biotechnology company focused on the generation of proprietary organisms for product development using a patented platform technology that can enhance the natural process of genetic evolution within a targeted host. The technology has been successfully applied to microbes, plants, and mammals to yield genetically diverse offspring that are suitable for pharmaceutical and agricultural product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.

For Information Contact:
Dr. Nicholas C. Nicolaides, President, CEO and CSO
Morphotek Inc.
610-423-6102

Back to 2003 News Archive